SCHEMBL20119935

SCHEMBL20119935

Cc1cn(CCO)c2nc(Cl)nc(NCc3ccncn3)c12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 3/20 0.36
CCNE1 P24864 2/20 0.36
JAK2 O60674 1/20 0.36
IGF1R P08069 1/20 0.36
PIM1 P11309 1/20 0.36
SRC P12931 1/20 0.36
CSNK2A2 P19784 1/20 0.36
KCNA5 P22460 1/20 0.36
JAK1 P23458 1/20 0.36
TYK2 P29597 1/20 0.36
FLT4 P35916 1/20 0.36
FLT3 P36888 1/20 0.36
MAP3K8 P41279 1/20 0.36
CSNK1A1 P48729 1/20 0.36
GSK3B P49841 1/20 0.36
JAK3 P52333 1/20 0.36
PLK1 P53350 1/20 0.36
CSNK2A1 P68400 1/20 0.36
CDK5 Q00535 1/20 0.36
BTK Q06187 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119664 0.89 KCNH3 (0.38) CDK2CCNE1JAK2IGF1RPIM1
SCHEMBL20119888 0.85 ESR1 (0.42) CDK2CCNE1PDE2AYTHDC1CDK1
SCHEMBL20119750 0.82 PDE2A (0.40) CDK2CCNE1JAK2IGF1RPIM1
SCHEMBL20119716 0.78 HRH4 (0.39) CDK2CCNE1PDE2AYTHDC1CDK1
SCHEMBL20119396 0.76 KMT2A (0.49) CHRM4ADORA3ADORA2AADORA2B
SCHEMBL20119808 0.75 CDK2 (0.41) CDK2CCNE1JAK2IGF1RPIM1
SCHEMBL20119730 0.73 PIM1 (0.38) CDK2CCNE1JAK2IGF1RPIM1
SCHEMBL20119746 0.73 PDE2A (0.40) CDK2CCNE1PDE2AYTHDC1CDK1
SCHEMBL20119914 0.72 PDE2A (0.43) CDK2CCNE1JAK2IGF1RPIM1
SCHEMBL20119422 0.70 KCNH3 (0.41) CDK2CCNE1JAK2IGF1RPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 CDK2 3622/4885CCNE1 4220/4885JAK2 4665/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 CDK2 3622/4885CCNE1 4220/4885JAK2 4665/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 CDK2 3622/4885CCNE1 4220/4885JAK2 4665/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 CDK2 3622/4885CCNE1 4220/4885JAK2 4665/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 CDK2 3622/4885CCNE1 4220/4885JAK2 4665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.